Related Experiment Video
Updated: Feb 24, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Systematic Review and Single-Arm Meta-Analysis of Bevacizumab Combined with Chemotherapy or Immunotherapy for
Yuling Gu1, Yunxian Tang1, Cui Zheng1
1Gynecologic Department, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Jiangsu, China.
Abstract:
The study aimed to evaluate the oncological outcomes related to bevacizumab-based combination therapy among patients with advanced or recurrent ovarian clear cell carcinoma (OCCC). PubMed, Web of Science, Cochrane Library and Embase were searched, and the Newcastle-Ottawa Scale (NOS) was utilized to assess the study quality. Results showed that bevacizumab significantly improved overall survival (OS) (HR = 0.51; 95% CI: 0.40-0.66) and progression-free survival (PFS) (HR = 0.42; 95% CI: 0.29-0.60). The overall objective response rate (ORR), complete response (CR), and partial response (PR) were 49% (95% CI: 39-60%), 17% (95% CI: 9-25%), and 31% (95% CI: 22-41%). Bevacizumab-based combination therapy may be a prospective strategy for advanced or recurrent OCCC.
More Related Videos
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...

